Strong sales growth and increased profit margins drive profitability upwards
GOTHENBURG, Sweden, Nov. 19, 2025 /PRNewswire/ — Revenue for the third quarter of 2025 amounted to SEK 784.1 (532.8) million, corresponding to 47% (22%) growth compared with the same period last year. In local currencies, revenue for the third quarter increased by 53% compared with the corresponding period last year. EBITDA increased to SEK 109.7 (63.0) million after the EBITDA margin increased to 14.0% (11.8%). The improved EBITDA margin compared to the corresponding period last year was mainly due to stronger gross profit and increased synergies, primarily related to the acquisition of Zurvita. During the quarter, Zinzino also acquired the assets of the US-based direct sales companies Bodē Pro and Truvy to increase distribution power in North America, Latin America, South Korea and Japan.
JULY-SEPTEMBER
JANUARY-SEPTEMBER
EVENTS AFTER THE REPORTING DATE
Link to the report:
https://www.zinzino.com/site/SE/sv-SE/om-oss/investerare/
For more information, please contact:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.com
Fredrik Nielsen CFO Zinzino +46 707 900 174, fredrik.nielsen@zinzino.com
Images for free publication: marketing@zinzino.com
Certified Adviser: DNB Carnegie Investment Bank AB (publ.)
This information is information that Zinzino AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 10 AM CET on November 19, 2025.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
en-zinzino-Q3-2025 |
|
|
|
1911 Pressrelease Interim Report Q3 EN |
SOURCE Zinzino
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…